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Antibacterial activitiesAbstract A series of 1-thiocarbamoyl-3-phenyl-5-hydroxy-5-(2-pyridyl)-4-pyrazolines derivatives
have been synthesized using sodium acetate as a catalyst. The spectral characterization and struc-
ture of 1-thiocarbamoyl-3-phenyl-5-hydroxy-5-(2-pyridyl)-4-pyrazolines are reported. Spectral
techniques employed include 1H NMR, 13C NMR, 1H–1H COSY, HSQC, HMBC, D2O exchange,
Mass and IR. Compounds 12–22 exhibited potent antibacterial activity against Salmonella typhi
and Pseudomonas aeruginosa whereas the same set of compounds exerted potent antifungal activity
against Aspergillus niger and Aspergillus fumigatus.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Heterocyclic analogues of chalcones were prepared for biologi-
cal studies (Dhar et al., 1981; Raut, 1960; Ariyan and uschitzky,
1961; Jurasek et al., 1978). N-thiocarbamoyl pyrazolines are
considered as important compounds in the organic chemistry
because of their application in heterocyclic synthesis and medi-
cine, pyrazolines are compounds with note worthy application
and have been reported to show a wide spectrum of biologicalactivities, including antibacterial, antifungal, anti inﬂamma-
tory, antiamoebic, antidepressant and anticonvulsant (Berghot
and Moawad, 2003; Nauduri and Reddy, 1998; Korgaokar
et al., 1996; Udupi et al., 1998, Abid and Azam, 2005; Bilgin
et al., 1993; Guniz et al., 2000). The pyrazoline function is a
quite stable fragment in bioactive moieties to synthesize new
compounds possessing biological activities. This prompted us
to synthesize various substituted N-thiocarbamoyl pyrazolines.
Over the years the synthesis of 2-pyrazoline has received consid-
erable attention. But while attempting to synthesize 2-pyrazo-
line derivatives using 2-acetyl pyridine based chalcones as
precursors, we accidentally got these new 4-pyrazoline deriva-
tives. So, herein we report an efﬁcient approach to synthesize
1-thiocarbamoyl-5-hydroxy-5-(-2-pyridyl)-4-pyrazoline deriva-
tives. Moreover there is no example in the literature for the syn-
thesis of 1-thiocarbamoyl-5-hydroxy-4-pyrazoline.
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2.1. Instruments
The IR spectrum was recorded in AVATAR-330 FT-IR spec-
trophotometer and only noteworthy absorption levels (recipro-
cal centimetres) were listed. 1H NMR spectra were recorded at
400&500 MHz on Bruker AMX 400&500 MHz spectropho-
tometer using CDCl3 as solvent and TMS as internal standard.
13C-NMR spectra were recorded at 100&125 MHz on Bruker
AMX 400&500 MHz spectrophotometer using CDCl3.
1H–1H COSY, one-bond 1H–13C correlation spectra, HMBC
and D2O exchange were recorded on bruker AMX 400
NMR spectrometer using standard parameters. 0.05 M solu-
tions of the sample prepared using CDCl3 were used for
recording 2D NMR spectra. The tubes used for recording
NMR spectra were 5 mm in diameter. The Chemical ionization
(CI) Mass spectra were recorded on a VARIAN-SATURN
2200 GC–MS spectrometer. The reactions and the purity of
the products were assessed by performing TLC. All the re-
ported melting points were taken in open capillaries and were
uncorrected.
3. Synthesis
3.1. Synthesis of 1-phenyl-3-(2-pyridyl) prop-2-en-1-one (1–10)
A mixture of 2-acetyl pyridine (0.01 mol) and substituted benz-
aldehyde (0.01 mol) was stirred in ethanol (50 mL) and then
aqueous solution of sodium hydroxide (10% 1 mL) was added
at room temperature and again stirred for 15 min. The
resulting solid was ﬁltered, washed with water, dried and
recrystallized from ethanol. Thus the characterization of
1-phenyl-3-(2-pyridinyl) prop-2-en-1-one (1–6) is reported
(Rajendra prasad et al., 2008).
3.1.1. 3-(4-methylphenyl)-1-(2-pyridyl) prop-2-en-1-one (7)
Yield: 78%; mp: 143 C; pale yellow solid; molecular formula
C15H13ON; IR tmax(cm
1): 1545 (C‚N); 1730 (C‚O); 1655 (–
CH‚CH); 1H NMR (CDCl3) d(ppm): 2.5 (s, 3H, CH3); 7.25
(d, 1H, C-30-H); 7.27 (d, 1H, CO–CH‚); 7.94 (s, 1H, C-2-
H); 7.65 (d, 1H, C-40-H); 7.72 (m, 1H, C-50-H); 7.83 (d, 1H,
C-6-H); 8.25 (m, 1H, C-5-H); 8.67 (d, 1H, C-4-H); 8.53 (d,
1H, C-60-H).
3.1.2. 3-(4-N, N-dimethylaminophenyl)-1-(2-pyridyl) prop-2-
en-1-one (8)
Yield: 75%; mp: 135 C; pale yellow powder; molecular for-
mula C16H16ON2; IR tmax(cm
1): 1515 (C‚N); 1725
(C‚O); 1643 (–CH‚CH); 1H NMR (CDCl3) d(ppm): 2.9 (s,
6H, (CH3)2); 7.25 (d, 1H, C-3
0-H); 7.45 (d, 1H, CO–CH‚);
7.53 (d, 1H, C-6-H); 7.85 (s, 1H, C–3–H); 7.95 (m, 2H, C-40-
H, C-5’-H); 8.25 (d, 1H, C-5-H); 8.33 (d, 1H, ‚CH–Ar);
8.77 (d, 1H, C-60-H).
3.1.3. 3-(3-nitrophenyl)-1-(2-pyridyl)prop-2-en-1-one (9)
Yield: 82%; mp: 110 C; yellow solid; molecular formula
C14H10O3N2; IR tmax(cm
1): 1545 (C‚N); 1733 (C‚O);
1659 (–CH‚CH); 1H NMR (CDCl3) d(ppm): 7.29 (d, 1H,
C-30-H); 7.25 (d, 1H, CO–CH‚); 7.11 (s, 1H, C-2-H); 7.54(d, 1H, C-40-H); 7.65 (m, 1H, C-50-H); 7.85 (d, 1H, C-6-H);
8.14 (m, 1H, C-5-H); 8.29 (d, 1H, ‚CH–Ar); 8.67 (d, 1H,
C-4-H); 8.79 (d, 1H, C-60-H).
3.1.4. 3-(4-nitrophenyl)-1-(2-pyridyl)prop-2-en-1-one (10)
Yield: 80%; mp: 115 C; yellow solid; molecular formula
C14H10O3N2; IR tmax(cm
1): 1548 (C‚N); 1735 (C‚O);
1661 (–CH‚CH); 1H NMR (CDCl3) d(ppm): 7.33 (d, 1H,
C-30-H); 7.21 (d, 1H, CO–CH‚); 7.13 (s, 1H, C-2-H); 7.55
(d, 1H, C-40-H); 7.63 (m, 1H, C-50-H); 7.83 (d, 1H, C-6-H);
8.17 (m, 1H, C-5-H); 8.27 (d, 1H, ‚CH–Ar); 8.65 (d, 1H,
C-4-H); 8.76 (d, 1H, C-60-H).
3.2. Synthesis of 3-(3, 4-dimethoxy phenyl)-1-(2-naphthyl)
prop-2-en-1-one (11)
A mixture of 2-acetyl naphthalene (0.1 mm) and 3, 4-dime-
thoxy benzaldehyde (0.1 mm) in ethanol was stirred for
10 min in the presence of 10% sodium hydroxide (5 mL).
The solution is cooled and the product was ﬁltered and recrys-
tallized from ethanol.
Scheme 2
Figure 1 Numbering of the 4-pyrazoline (12).
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C21H18O3; tmax cm
1 1729 (C‚O), 1655 (HC‚CH),
3067(HC‚); 1H NMR (500 MHZ CDCl3) d(ppm): 6.77
(d,1H, J= 9.1, HC‚CH), 7.49–7.66(m, 7H, aromatic),
7.85–8.11 (m, 3H, aromatic) 8.19 (d, 1H, J= 9.0 CO–
CH‚CH), 3.8 (s, 6H, (OCH3)2;
13C NMR (125 MHZ CDCl3)
d(ppm): 189.07 (C‚O), 111.8 and 117.77(CH‚CH),
55.19,55.25(OCH3)2, 122.7, 124.8, 126.6, 127.8, 128.11,128.56, 129.7, 129.9, 130.6, 132.7, 135.4, 136.7, 139.4, and
140.3 (aromatic carbons);GC–MS (m/z): 318.
3.3. General procedure for the synthesis (12–21)
Synthesis of pyrazoline derivatives was performed in a manner
as outlined in Scheme 2. The cyclization of chalcones (1–10)
with thiosemicarbazide under basic condition (saturated
CH3COONa) in 50 mL of ethanol led to the formation of pyr-
azoline derivatives and all the compounds were stable in solid
state. The structure of pyrazoline derivatives (12–21) is shown
in Fig. 1.
3.4. Synthesis of 1-thiocarbamoyl 3-(3, 4-dimethoxyphenyl)-5-
hydroxyl (-2-pyridyl)-4-pyrazoline (12)
Compound as yellow powder; mp 204 C; yield 80%; mf
C17H18N4O3S; tmax cm
1 1617 (C‚N), 3170 (HC‚Ar),
S602 D. Chinnaraja et al.3273,3347 (NH2);
1H NMR (400 MHZ CDCl3) d(ppm): 3.6 (d,
1H, J= 18 HZ, HA), 3.7 (d, 1H, J= 18 HZ, HB), 3.9 (s, 6H,
(OCH3)2), 6.7 (s, 1H, –OH); 6.0–7.1 (broad signals, 2H,
NH2), 6.8–8.5 (m, 7H, Ar–H);
13C NMR (100 MHZ CDCl3)
d(ppm): 161.61 (C‚N), 175.19, (C‚S), 50.13(C-4), 95.22 (C-
5), 56.14, 56.16 ((OCH3)2), 151.89 153.22 (ipso carbons),
110.81–149.37.(aromatic carbons); Anal. Calcd. (%) for: C,
56.97; H, 5.06; N, 15.63. Found (%): C, 56.71; H, 5.01; N,
15.42; GC/MS (m/z): 341.1. and loss of –OH group.
3.5. Synthesis of 1-thiocarbamoyl-3-(4-methoxyphenyl)-5-
hydroxy-5-(2-pyridyl)-4-pyrazoline (13)
Compound as yellow powder; mp 184 C; yield 70%; mf
C16H16N4O2S; tmax cm
1 1620 (C‚N), 3167 (HC‚Ar),
3336–3419 (NH2);
1H NMR (500 MHZ CDCl3) d(ppm): 3.6
(d, 1H, J= 18 HZ, HA), 3.7 (d, 1H, J= 18 HZ, HB), 3.8 (s,
3H, (OCH3)), 6.7 (s, 1H, –OH); 5.9–7.1 (broad signals, 2H,
NH2), 6.9–8.5 (m, 8H, Ar–H);
13C NMR (125 MHZ CDCl3)
d(ppm): 161.88 (C‚N), 175.01, (C‚S), 50.00(C-4), 94.98 (C-
5), 55.43 (OCH3), 136.48, 149.21, 152.91 (ipso carbons),
114.22–128.71 (aromatic carbons).
3.6. Synthesis of 1-thiocarbamoyl-3-(3, 4, 5-trimethoxyphenyl)-
5-hydroxy-5-(2-pyridyl)-4-pyrazoline (14)
Compound as yellow powder; mp 209 C; yield 65%; mf
C17H20N4O4S; tmax cm
1 1620 (C‚N), 3173 (HC‚Ar),
3271–3343 (NH2);
1H NMR (500 MHZ CDCl3) d(ppm): 3.6
(d, 1H, J= 18 HZ, HA), 3.7 (d, 1H, J= 18 HZ, HB), 3.8 (s,
9H, (OCH3)3), 6.7 (s, 1H, –OH); 6.0–7.2 (broad signals, 2H,
NH2), 6.8–8.5 (m, 7H, Ar–H);
13C NMR (125 MHZ CDCl3)
d(ppm): 161.50 (C‚N), 175.11(C‚S), 51.15(C-4), 95.33(C-
5), 56, 11, 56.19, 56.25(OCH3)3, 149.21, 152.91 (ipso carbons),
114.22–128.71(aromatic carbons).
3.7. Synthesis of 1-thiocarbamoyl-3-(4-chlorophenyl)-5-
hydroxy-5-(2-pyridyl)-4-pyrazoline (15)
Compound as white powder; mp 168 C; yield 65%; mf
C15H13N4OSCl; tmax cm
1 1627 (C‚N), 2923 (HC‚),
3315–3405 (NH2);
1H NMR (500 MHZ CDCl3) d(ppm): 3.6
(d, 1H, J= 18.3 HZ, HA), 3.7 (d, 1H, J= 18 HZ, HB), 6.6
(s, 1H, –OH); 6.0–7.1 (broad signals, 2H, NH2), 7.1–8.5 (m,
8H, Ar–H); 13C NMR (125 MHZ CDCl3) d(ppm):
161.22(C‚N), 175.56(C‚S), 49.76(C-4), 95.27 (C-5), 148.87,
149.22, 151.90 (ipso carbons), 120.15–137.06 (aromatic car-
bons); GC–MS (m/z): 317.9, and loss of –OH group.
3.8. Synthesis of 1-thiocarbamoyl-3-(2, 4-dichlorophenyl)-5-
hydroxy-5-(2-pyridyl)-4-pyrazoline (16)
Compound as white powder; mp 115 C; yield 65%; mf
C15H12N4OSCl2; tmax cm
1 1625 (C‚N), 2929 (HC‚Ar),
3319–3409(NH2);
1H NMR (500 MHZ CDCl3) d(ppm): 3.6
(d, 1H, J= 18.5 HZ, HA), 3.7 (d, 1H, J= 18 HZ, HB), 6.6
(s, 1H, –OH); 6.1–7.2 (broad signals, 2H, NH2), 7.1–8.5 (m,
7H, Ar–H); 13C NMR (125 MHZ CDCl3) d(ppm):
162.27(C‚N), 175.23(C‚S), 49.13(C-4), 95.09 (C-5), 148.86,
149.66, 152.80 (ipso carbons), 120.17–137.76 (aromatic
carbons).3.9. Synthesis of 1-thiocarbamoyl 3-(4-methylphenyl)-5-
hydroxyl (-2-pyridyl)-4-pyrazoline (17)
Compound as yellow powder; mp 127 C; yield 80%; mf
C16H16N4OS; tmax cm
1 1613 (C‚N), 3175 (HC‚Ar),
3273,3347 (NH2);
1H NMR (400 MHZ CDCl3) d(ppm): 3.6
(d, 1H, J= 18 HZ, HA), 3.7 (d, 1H, J= 18 HZ, HB), 2.5 (s,
3H, (CH3), 6.6 (s, 1H, –OH); 6.0–7.1 (broad signals, 2H,
NH2), 6.8–8.5 (m, 7H, Ar–H);
13C NMR (100 MHZ CDCl3)
d(ppm): 162.61 (C‚N), 174.19, (C‚S), 51.13(C-4), 95.13 (C-
5), 56.14, 15.16 (CH3), 151.89 153.22 (ipso carbons), 112.81–
149.77 (aromatic carbons).
3.10. Synthesis of 1-thiocarbamoyl-3-(4-N,N-dimethylphenyl)-
5-hydroxy-5-(2-pyridyl)-4-pyrazoline (18)
Compound as yellowish orange powder; mp 104 C; yield
70%; mf C17H19N5OS; tmax cm
1 1621 (C‚N), 3187
(HC‚Ar), 3332,3415 (NH2);
1H NMR (500 MHZ CDCl3)
d(ppm): 3.6 (d, 1H, J= 18 HZ, HA), 3.7 (d, 1H, J= 18 HZ,
HB), 2.9 (s, 6H, (CH3)2), 6.6 (s, 1H, –OH); 6.0–7.2 (broad sig-
nals, 2H, NH2), 6.9–8.6 (m, 9H, Ar–H);
13C NMR (125 MHZ
CDCl3) d(ppm): 160.88 (C‚N), 177.01, (C‚S), 51.00(C-4),
95.98 (C-5), 43.13 (CH3), 136.48, 149.21, 152.91 (ipso carbons),
113.22–129.71 (aromatic carbons).
3.11. Synthesis of 1-thiocarbamoyl-3-(4-Bromophenyl)-5-
hydroxy-5-(2-pyridyl)-4-pyrazoline (19)
Compound as white powder; mp 133 C; yield 75%; mf
C15H13N4OSBr; tmax cm
1 1626 (C‚N), 2921 (HC‚),
3315,3405 (NH2);
1H NMR (500 MHZ CDCl3) d(ppm): 3.7
(d, 1H, J= 18.3 HZ, HA), 3.8 (d, 1H, J= 18 HZ, HB), 6.7
(s, 1H, –OH); 6.0–7.1 (broad signals, 2H, NH2), 7.1–8.5 (m,
8H, Ar–H); 13C NMR (125 MHZ CDCl3) d(ppm):
162.22(C‚N), 176.56(C = S), 50.76(C-4), 96.27 (C-5),
148.87, 149.22, 151.90 (ipso carbons), 120.15–137.06 (aromatic
carbons).
3.12. Synthesis of 1-thiocarbamoyl-3-(3-nitrophenyl)-5-
hydroxy-5-(2-pyridyl)-4-pyrazoline (20)
Compound as yellow powder; mp 117 C; yield 65%; mf
C15H13N5O3S; tmax cm
1 1627 (C‚N), 2921 (HC‚),
3317,3406 (NH2);
1H NMR (500 MHZ CDCl3) d(ppm): 3.6
(d, 1H, J= 18.3 HZ, HA), 3.7 (d, 1H, J= 18 HZ, HB), 6.8
(s, 1H, –OH); 6.0–7.1 (broad signals, 2H, NH2), 7.0–8.6 (m,
8H, Ar–H); 13C NMR (125 MHZ CDCl3) d(ppm):
160.22(C‚N), 174.56(C‚S), 51.76(C-4), 96.27 (C-5), 149.87,
151.22, 152.90 (ipso carbons), 120.15–137.06 (aromatic
carbons).
3.13. Synthesis of 1-thiocarbamoyl-3-(4-Nitrophenyl)-5-
hydroxy-5-(2-pyridyl)-4-pyrazoline (21)
Compound as yellow powder; mp 177 C; yield 60%; mf
C15H13N5O3S; tmax cm
1 1626 (C‚N), 2926 (HC‚Ar),
3329, 3993(NH2);
1H NMR (500 MHZ CDCl3) d(ppm): 3.6
(d, 1H, J= 18.5 HZ, HA), 3.7 (d, 1H, J= 18 HZ, HB), 6.6
(s, 1H, –OH); 6.1–7.2 (broad signals, 2H, NH2), 7.1–8.5 (m,
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Figure 2 Numbering of 2-pyrazoline (22).
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161.27(C‚N), 176.23(C‚S), 50.13(C-4), 95.09 (C-5), 148.86,
149.66, 152.80 (ipso carbons), 120.17–137.76 (aromatic
carbons).
3.14. Synthesis of 1-thiocarbamoyl-3-naphthyl-5-(3, 4-
dimethoxyphenyl) -2-pyrazoline (22)
Synthesis of pyrazoline derivative was performed in a manner
as outlined in (Scheme 3). The cyclization of chalcones (11)
with thiosemicarbazide under basic condition (saturated
CH3COONa) in 50 mL of ethanol led to the formation of pyr-
azoline compound which was stable in solid state. The struc-
ture of pyrazoline compound 22 is shown in Fig. 2.
Compound as yellow wish brown solid; mp 74 C; yield
65%; mf C22H21N3O2S; tmax cm
1 1589 (C‚N), 3057
(HC‚Ar), 3440–3369 (NH2);
1H NMR (400 MHZ CDCl3)d(ppm): 3.4 (dd, 1H, J1 = 3.6HZ, J2 = 17.6HZ, HA), 4.1 (dd,
1H, J1 = 3.3HZ, J2 = 17.3HZ HB), 6.0 (dd, 1H, J1 = 3.2HZ,
J2 = 11.2HZ Hc), 3.84, 3.85 (s, 6H, (OCH3)2), 8.9 (d, 2H,
J= 8.4, NH2), 6.9–7.9 (m, 9H, Ar–H);
13C NMR (100 MHZ
CDCl3) d(ppm): 155.90 (C‚N), 175.91, (C‚S), 61.30(C-4),
108.10(C-5), 54.87, 54.91 ((OCH3)2), 148.30 (ipso carbon),
116.57–133.28 (aromatic carbons); GC/MS (m/z): 390.
3.2. Biological activity
The in vitro activities of the compounds were tested in Sabou-
raud’s dextrose broth (SDB) (Hi-media, Mumbai) for fungi
and Sabouraud’s dextrose agar (SDA) for bacteria by the
two fold serial dilution method (Dhar et al., 1968). The test
compounds were dissolved in dimethyl sulfoxide (DMSO) to
obtain 1 mg/mL stock solution. Seeded broth (broth contain-
ing microbial spores) was prepared in SDA from 24 objective
old bacterial cultures on nutrient agar (Hi-media, Mumbai) at
37 ± 1 C while fungal spores of 1–7 days old were suspended
in SDA. The colony forming units (cfu) of the seeded broth
were determined by the plating technique and adjusted in the
range of 103–107 cfu/mL. The ﬁnal inoculum six was 107 cfu/
mL for antifungal assay. Testing was performed at pH 8 of
the solution of test compound was added to 1.8 ml of seeded
broth to form the ﬁrst dilution. One millilitre of this was di-
luted with a further 1 mL of the seeded broth to give the sec-
ond dilution and so on till dilutions of desired volume were
obtained. A set of assay tubes containing only incubated broth
was kept as control and likewise solvent controls were also
used simultaneously. The tubes were incubated in BOD incu-
bators at 37 C for bacteria and 28 C for fungi. Amikacin
and amphotericin were used as standards.4. Results and discussion
4.1. Spectral analysis
Generally chalcones show differential reactivity towards thio-
semicarbazide (Shivarama Holla et al., 2000), they can lead
to two different pyrazolines as shown in Scheme 1 (Rezessy
et al., 2000). The synthesis of 2-pyrazoline derivatives from
2-acetyl pyridine based chalcones using KOH as catalyst has
also been reported (Wang et al., 2011). (Scheme 1, route-A).
In the present investigation the condensation of 2-acetyl
pyridine based chalcones with thiosemicarbazide in the pres-
ence of saturated sodium acetate yields 5-hydroxy-4-pyrazoline
(12). But the chalcones derived from 2-acetyl naphthalene with
thiosemicarbazide under the same reaction conditions give 2-
pyrazoline as expected. But in the present study the reaction
of 2-acetyl pyridine with thiosemicarbazide follows route-B.
But the reaction does not proceed up to completion and
stops before (12) is transformed into 2-pyrazoline derivative
this may be due to the intramolecular hydrogen bonding be-
tween the nitrogen atom of the pyridine ring and the hydroxyl
group at C-5 carbon. The hydroxyl group may also be in a
hydrogen bonding with the hydrogen atom of the thiocarba-
moyl group. The hydroxyl is not in a free state to be eliminated
as water so the reaction stopped at this stage and gives 5-hy-
droxyl-4-pyrazoline derivatives. Compound (12) formed is
not the excepted product and the formation of (12) can be
rationalized as shown in Scheme 2.
Table 1 Antibacterial activity of thiocarbamoyl compounds (12–22).
Compounds Zone of inhibition (mm)
S. typhi S. aureus E. coli K. pneumoniae Pseudomonas
12 1.5 2.5 1.0 1.0 1.5
13 1.0 2.0 2.0 2.0 1.2
14 3.1 2.5 2.5 2.0 1.2
15 2.5 2.5 2.5 2.5 3.1
16 2.5 2.0 2.5 1.0 1.5
17 2.5 2.5 2.0 1.5 2.5
18 2.5 2.5 1.5 2.5 2.5
19 1.5 1.0 1.0 2.0 1.2
20 1.2 1.2 1.2 1.0 1.2
21 1.2 1.2 1.5 1.2 1.2
22 2.3 1.5 2.0 1.5 1.2
Amikacin 1.00 2.5 2.5 1.00 1.00
Table 2 Antifungal activity of thiocarbamoyl compounds
(12–22).
Compounds Zone of inhibition (mm)
A. ﬂavus C. albicans A. fumigatus A. niger
12 1.0 2.0 2.5 2.5
13 2.0 2.5 1.0 1.5
14 2.5 2.5 2.0 1.5
15 2.5 2.5 2.5 3.1
16 1.0 1.0 2.0 2.5
17 2.0 1.0 1.0 2.5
18 2.5 2.5 2. 2.5
19 1.0 2.5 2.5 2.5
20 2.0 2.5 2.5 2.5
21 2.5 2.0 1.0 2.5
22 2.5 2.5 2.5 1.0
Amphotericin 2.5 2.5 2.5 2.5
S604 D. Chinnaraja et al.For a safe differentiation the 1H NMR spectrum of both
12&22 is compared. The methine protons of the pyrazoline
ring (22) exhibits vicinal coupling with both the protons in
the methylene carbon which are in different environment
therefore it gives three doublets of doublet as excepted.
Whereas in the 1H NMR spectrum of hydroxy pyrazoline
(12) only two doublets are observed. From the HOMOCOSY
spectrum of compound 12 it is clear that the closely spaced
doublet at 3.6 and 3.7 ppm has cross peak mutually and it
should be due to the methylene protons. But in the HOMO-
COSY spectrum of compound 22, the double doublet at
6.0 ppm correlates both with the double doublet at 3.4 and
4.1 ppm, whereas there is only a doublet, instead of doublet
doublet in this region, in compound 12, proving the absence
of benzylic proton.
In the 13C NMR spectrum of compound 12 the signal at
50.13 ppm is assigned to methylene carbon (C-4) and the meth-
oxy carbon signals are observed at 56.14 and 56.16 ppm. The
signal observed at 161.1 ppm is due to (C‚N) carbon. The sig-
nal at 95.22 ppm is assigned to C-5 carbon and the signal at
175.19 ppm is due to the thiocarbamoyl carbon.
In the HSQC spectrum of compound 12 it can be noted that
the signal at 50.13 ppm has a cross peak with signals at
3.6 ppm and 3.7 ppm. Therefore the signal found at
50.13 ppm is due to methylene carbon (C-4). Anotherobservation is that the signal at 95.22 ppm does not show
any correlation with proton signal indicating the C-5 carbon.
Further evidence for this structure was obtained from the
HMBC spectrum, allows the presence of carbon–proton
coupling over two or three bonds.
The peak at 95.22 ppm has a cross peak with signal at
6.71 ppm and the peak at 50.13 ppm also has cross peak with
signal at 6.71 ppm. But in the HSQC spectrum there is no cor-
relation between the signal at 95.22 and 6.71 ppm. It indicates
that the proton is not attached directly to carbon. This is due
to the proton attached to hetero atom. Besides, the signal at
6.71 ppm in 1H NMR spectrum is due to –OH proton and it
is attached to C-5 carbon appearing at 95.22 ppm. It is also
very clear that the C-5 carbon is attached to C-4 carbon which
is appearing at 50.13 ppm. This is because the signal at
95.22 ppm also has a cross peak with signals at 3.6 and
3.7 ppm which inturn are the signals of protons attached to
C-4 carbon appearing at 50.13 ppm.
In the mass spectrum of compound 22 the peak observed at
m/z= 390 is due to the molecular ion. In the mass spectrum of
compound 12 there is no discernible molecular ion peak. But
the base peak observed at m/z= 341.1 is due to loss of –OH
group [(M+-17) (358–17)]. This also proves that the thiocarba-
moyl group of 12 is not in a free state to be eliminated during
ionization as it is involved in hydrogen bonding.
4.2. Biological activity
All synthesized compounds (12–21 and 22) are tested for their
antibacterial activity against Salmonella typhi, Stapylococcus
aureus, Escheriachia coli, Klebsiella pneomoniae and Pseudomo-
nas aeruginosa as well as antifungal activities against Aspergil-
lus ﬂavus, Candida albicans, Aspergillus niger and Aspergillus
fumigatus. The zone of inhibition (mm) of compound 12–21
and 22 against all tested in microorganism is given in Table 1.
The compounds 12–21 and 22 were tested for their antibac-
terial activity against S. aureus, E. coli, K. pneumoniae, S. typhi
and P. aeruginosa. It is clear that the compounds 12–18
showed very good activity against S. typhi and S. aureus when
compared to the standard. But the compounds 19–22 have a
very less activity against all tested organisms.
From the diameter of zone of inhibition (Table 2) of tested
compounds 12–21 and 22 it is inferred that they showed very
good activity against A. niger compared to the standard, but
Synthesis, spectral characterization and biological evaluation S605their activity against all other fungal strains was found to be
very poor when compared to the standard amphotericin.
5. Conclusion
It can be concluded that starting with chalcones derived from
2-acetyl pyridine 5-hydroxy-4-pyrazoline derivatives (12) can
be obtained via Michael addition whereas the 2-pyrazoline
derivatives (22) were not formed. The same 5-hydroxy-4-pyr-
azoline derivatives (12) can be isolated though this can be
transformed into corresponding pyrazoline derivatives. On
the other hand cyclization of 2-acetyl naphthalene based chal-
cones under the same set of reaction conditions proceeds via
hydrozone (route-A) and yields the excepted 2-pyrazoline
derivative. So it is clear that the intramolecular hydrogen
bonding between the nitrogen atom of the pyridine ring and
the hydroxyl group at the C-5 carbon prevents the reaction
to proceed further and to give the dehydrated product 2-pyraz-
oline derivative. Antibacterial and antifungal studies show that
the synthesized compounds 12–21 and 22 exhibit maximum
activity of inhibition against the reported bacterial and fungal
strains.Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/
j.jscs.2013.04.006.References
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